Abiomed's percutaneous heart pump clears Health Canada

Justine Varieur Cadet | | Cardiovascular Business | Heart Failure
Abiomed, a developer of heart support technologies, has received Health Canada approval to market the Impella cVAD device, a percutaneous Impella heart pump.

The Impella cVAD1 is designed to provide temporary circulatory support via a catheter-based pump that is inserted percutaneously. cVAD seeks to provide peak flow of approximately four liters of blood per minute, according to the Danvers, Mass.-based company.

The Impella cVAD is not currently cleared for sale or use in the U.S.

Justine Varieur Cadet

Related Content

Medtronic using AI to identify more TAVR patients in need
Tirzepatide linked to significant weight loss, ‘impressive’ diabetes prevention after 3 years
Most heart failure patients miss out on guideline-recommended palliative care
CMS updates outpatient reimbursement policy for Barostim device
American Heart Association announces late-breaking research for Scientific Sessions 2024
Impella ECP confirmed to be safe for high-risk PCI—is FDA approval next?

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Design by Adaptive Theme
Trimed Popup
Trimed Popup